Ponatinib leukaemia drug molecule. Computer model showing the structure of a molecule of the tyrosine-kinase inhibitor (TKI) ponatinib. TKIs are the f
Ponatinib leukaemia drug molecule. Computer model showing the structure of a molecule of the tyrosine-kinase inhibitor (TKI) ponatinib. TKIs are the first-line therapy for most patients with chronic myelogenous leukaemia (CML), a form of blood cancer. Ponatinib is used for the treatment of CML and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Atoms are represented as rods and are colour-coded: fluorine (pale green), sulphur (yellow), oxygen (red), nitrogen (blue), carbon (green).
Size: 3541px × 5007px
Photo credit: © RAMON ANDRADE 3DCIENCIA/SCIENCE PHOTO LIBRARY / Alamy / Afripics
License: Licensed
Model Released: No
Keywords: -, alpha, artwork, background, biochemical, biochemistry, biological, biology, cancer, chemotherapy, chronic, cml, cut, cut-, cut-outs, cutout, cutouts, drug, helix, illustration, inhibitor, leukaemia, leukemia, lymphoblastic, medical, medicine, model, molecular, molecule, myelogenous, oncological, oncology, outs, pharmaceutical, pharmaceutics, pharmacological, pharmacology, ponatinib, quaternary, secondary, single, structure, therapy, tki, treatment, tyrosine-kinase, white